Market Research Logo

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides

- you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure-induced pain; OX-CLI for respiratory tract diseases; and OX-MPI for inflammation. The company employs its proprietary drug delivery technologies in the development of these products. It also carries out the industrial-scale production of pharmaceutical products. Orexo works in collaboration with various pharmaceutical companies including, Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jul 11,2018: Orexo: Interim Report Q2 2018
May 31,2018: Orexo's CFO resigns and will leave the company in November 2018
Apr 26,2018: Orexo - Interim Report Q1 2018
Feb 06,2018: Orexo participating in new project concerning R&D for Drug Delivery technologies in collaboration with Uppsala University
Jan 25,2018: Orexo: Full Year Report Q4 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Orexo AB - Key Facts
Orexo AB - Key Employees
Orexo AB - Key Employee Biographies
Orexo AB - Major Products and Services
Orexo AB - History
Orexo AB - Company Statement
Orexo AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Orexo AB - Business Description
Product Category: Abstral
Overview
Performance
Product Category: Edluar
Overview
Performance
Product Category: Zubsolv
Overview
Performance
Product Category: Milestone
Performance
Geographical Segment: East Asia
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
Orexo AB - SWOT Analysis
SWOT Analysis - Overview
Orexo AB - Strengths
Orexo AB - Weaknesses
Orexo AB - Opportunities
Orexo AB - Threats
Orexo AB - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Orexo AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 11, 2018: Orexo: Interim Report Q2 2018
May 31, 2018: Orexo's CFO resigns and will leave the company in November 2018
Apr 26, 2018: Orexo - Interim Report Q1 2018
Feb 06, 2018: Orexo participating in new project concerning R&D for Drug Delivery technologies in collaboration with Uppsala University
Jan 25, 2018: Orexo: Full Year Report Q4 2017
Oct 19, 2017: Orexo Interim Report Q3 2017
Sep 05, 2017: Orexo, together with Malmo University, receives research grant
Jul 11, 2017: Orexo Interim Report Q2 2017
Apr 20, 2017: Orexo: Interim Report Q1 2017
Jan 26, 2017: Orexo: Full Year Report 2016
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Orexo AB, Key Facts
Orexo AB, Key Employees
Orexo AB, Key Employee Biographies
Orexo AB, Major Products and Services
Orexo AB, History
Orexo AB, Subsidiaries
Orexo AB, Key Competitors
Orexo AB, Ratios based on current share price
Orexo AB, Annual Ratios
Orexo AB, Annual Ratios (Cont...1)
Orexo AB, Annual Ratios (Cont...2)
Orexo AB, Interim Ratios
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Orexo AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Orexo AB, Performance Chart (2013 - 2017)
Orexo AB, Ratio Charts
Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report